Cardiovascular disease is the world’s leading cause of death, making diagnosis and risk assessment a high priority. The prevailing theory of cardiovascular disease risk is the lipid hypothesis, which posits that elevations in apolipoprotein B (ApoB) and low-density lipoprotein cholesterol (LDL-C) are significant risk factors that should be primary treatment targets. However, this new research questions the relevance of the lipid hypothesis in metabolically healthy individuals whose cholesterol levels rise in response to a low-carb ketogenic diet–often adopted to address significant mental or physical health challenges. As evidence accumulates for the efficacy of therapeutic carbohydrate reduction to improve chronic conditions like diabetes or inflammatory bowel disease, investigating the cardiovascular risk of diet-induced high cholesterol has become critical.
Despite the striking beneficial effects that are seen following this therapy, adoption is often discouraged by medical doctors because of the presumed increased risk of heart disease. The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, in collaboration with researchers across multiple institutions, has published a new study that challenges the long-held belief that high cholesterol correlates and even directly causes coronary artery disease, or plaque buildup in the arteries in metabolically healthy individuals. The study recruited 100 metabolically healthy individuals following a long-term low-carbohydrate Ketodiet who developed elevated levels of LDL cholesterol–dubbed Lean Mass Hyper-Responders (LMHRs). The study investigated the relationship between LDL-C, ApoB and heart plaque progression in a subpopulation of people who adopt low carbohydrate diets and fit the LMHR phenotype.
This unique metabolic profile includes elevated LDL-C and ApoB levels despite otherwise healthy metabolic marker levels including low triglycerides, high HDL, low blood pressure, low insulin resistance, and low body mass index. The researchers found that traditional cholesterol markers (ApoB and LDL-C) were not associated with baseline heart disease or progression in this population. On the other hand, they found no association between plaque progression and total exposure to, changes in, or baseline levels of ApoB and LDL-C. Rather, baseline plaque burden was identified as the strongest predictor of future plaque progression. These findings suggest that high cholesterol is not always a marker of plaque progression and that individuals with the LMHR phenotype may benefit from cardiac imaging to further assess their cardiovascular risk.
The findings build on previous work from the research team demonstrating that LMHR individuals have similar levels of coronary plaque to a carefully-matched comparison group with normal LDL levels, underscoring that ketogenic diet-induced LDL increases may not indicate a higher risk of coronary plaque. The study points to a clear need to expand cardiovascular disease risk assessment to include a personalized approach that can prioritize cardiac imaging. The researchers also call for an open-minded multidisciplinary approach to better understanding the heart disease risk of individuals with the LMHR phenotype, who often rely on low carbohydrate and ketogenic diets to keep chronic disease at bay.
- Edited by Dr. Gianfrancesco Cormaci, PhD, specialist in Clinical Biochemistry.
Scientific references
Soto-Mota A et al. JACC Adv. 2025 Mar 18:101686.
Faridi KF et al. JACC Adv. 2024 Jun 13; 3(7):101049.
Sorokin AV et ael. JCI Insight. 2023; 8(20):e172893.
